Molecular and Cellular Advances in Gynecologic Cancer Research
Submission Deadline: 30 Sep 2023
Guest Editor
Special Issue Information
Dear Colleagues,
Gynecologic cancer can occur in any of a woman’s reproductive organs. The increasing incidence and mortality rates due to gynecologic cancers make it essential to understand the molecular and cellular biology of this specific cancer cell. With the advantages of rapidly developing molecular biology technologies, it is critical to explore and study the intricacies of a gynecologic cancer cell. This special issue aims to present recent research on the molecular and cellular advances in gynecologic cancer research that can assist in diagnosis, prognosis, and targeted therapies. We welcome all articles contributing to increasing the knowledge in this field.
Assoc. Prof. Padmanaban S. Suresh
Guest Editor
Keywords
- ovarian cancer
- endometrial cancer
- cervical cancer
- vulvar cancer
- vaginal cancer
- molecular pathology
- biomarkers
- cell biology
- genetics
- genomics
- proteomics
Manuscript Submission Information
Manuscripts should be submitted via our online editorial system at https://imr.propub.com by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted manuscripts should be well formatted in good English.
Published Papers (4)
SPARC is a Novel Prognostic Biomarker for Ovarian Cancer and Associated with Immune Signatures and Drug Response
Clin. Exp. Obstet. Gynecol. 2024, 51(3), 61; https://doi.org/10.31083/j.ceog5103061
(This article belongs to the Special Issue Molecular and Cellular Advances in Gynecologic Cancer Research)
The Mechanism and Dynamic Regulation of Epithelial to Mesenchymal Transition in Ovarian Cancer
Clin. Exp. Obstet. Gynecol. 2023, 50(12), 272; https://doi.org/10.31083/j.ceog5012272
(This article belongs to the Special Issue Molecular and Cellular Advances in Gynecologic Cancer Research)
AFF3 is a Prognostic Biomarker Correlated with Immune Infiltrates in Triple-Negative Breast Cancer
Clin. Exp. Obstet. Gynecol. 2023, 50(8), 165; https://doi.org/10.31083/j.ceog5008165
(This article belongs to the Special Issue Molecular and Cellular Advances in Gynecologic Cancer Research)
Molecular and Cellular Advances in Gynecologic Cancer Research
Clin. Exp. Obstet. Gynecol. 2023, 50(6), 122; https://doi.org/10.31083/j.ceog5006122
(This article belongs to the Special Issue Molecular and Cellular Advances in Gynecologic Cancer Research)
